Skip to main content
Premium Trial:

Request an Annual Quote

Genomenon, Deep 6 AI Forge Data Partnership for Clinical Trial Matching

NEW YORK – Genomenon said Thursday that it has entered into a data partnership with Deep 6 AI, a maker of artificial intelligence-based clinical trial acceleration software.

Under what the firms dubbed a proof-of-concept agreement, they will effectively explore  combining their technology in search of insights about conditions including cancer, Parkinson's disease, and Wilson's disease, according to a spokesperson for Ann Arbor, Michigan-based Genomenon.

Pasadena, California-based Deep 6 AI offers software that mines structured and unstructured patient records, and genomics and pathology data to support trial-feasibility site selection and patient recruitment. That firm will integrate with Genomenon's AI-powered Genomic Landscapes platform to match patients to trial inclusion/exclusion criteria and then rank trial candidates by match percentage.

"Our collaboration with Deep 6 AI will help patients who will benefit from matching knowledge, while our Genomic Landscapes enable pharma to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop [clinical diagnostics] for regulatory approval," Genomenon CEO Mike Klein said in a statement.

"Precision matching is at the heart of our mission to support precision medicine and rapidly deliver more targeted therapies to patients," said Jason Attanucci, Deep 6 AI's VP of life sciences. "Together, both Genomenon and Deep 6 AI will provide a combined, AI-driven understanding of disease, enabling actionable insight into their genetic drivers, clinical representation, and comorbidity."

Attanucci is scheduled to co-present at the CNS Summit Nov. 9 on results of a study highlighting Deep 6 AI's matching technology.

In September, Genomenon announced a partnership with AstraZeneca's Alexion Pharmaceuticals to apply Genomic Landscapes to diagnosis of rare diseases including Wilson's.

The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.